Centessa Pharmaceuticals, a clinical-stage biotech with a diversified portfolio and recent commercial licensing revenue, reported increased R&D spending and persistent operating losses in 2025. The company maintains strong liquidity supported by a loan facility but continues facing significant cash burn and operational risks typical of early-stage pharma firms. A pending acquisition by Eli Lilly marks a key near-term catalyst, with milestone-linked contingent payments providing additional upside potential. Management’s incentivization and strategic licensing underpin pipeline development, while supply chain dependencies and regulatory challenges remain notable risks.